Accessibility navigation


Blockade of ActRIIB signaling triggers muscle fatigability and metabolic myopathy

Relizani, K., Mouisel, E., Giannesini, B., Hourde, C., Patel, K., Morales Gonzales, S., Julich, K., Vignaud, A., Pietri-Rouxel, F., Fortin, D., Garcia, L., Blot, S., Ritvos, O., Bendahan, D., Ferry, A., Ventura-Clapier, R., Schuelke, M. and Amthor, H. (2014) Blockade of ActRIIB signaling triggers muscle fatigability and metabolic myopathy. Molecular Therapy, 22 (8). pp. 1423-1433. ISSN 1525-0024

[img]
Preview
Text - Accepted Version
· Please see our End User Agreement before downloading.

15MB

It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

To link to this item DOI: 10.1038/mt.2014.90

Abstract/Summary

Myostatin regulates skeletal muscle size via the activin receptor IIB (ActRIIB). However, its effect on muscle energy metabolism and energy dependent muscle function remains largely unexplored. This question needs to be solved urgently since various therapies for neuromuscular diseases based on blockade of ActRIIB signaling are being developed. Here we show in mice that four months of pharmacological abrogation of ActRIIB signaling by treatment with soluble ActRIIB-Fc triggers extreme muscle fatigability. This is associated with elevated serum lactate levels and a severe metabolic myopathy in the mdx mouse, an animal model of Duchenne muscular dystrophy. Blockade of ActRIIB signaling down-regulates Porin, a crucial ADP/ATP shuttle between cytosol and mitochondrial matrix leading to a consecutive deficiency of oxidative phosphorylation as measured by in vivo Phophorus Magnetic Resonance Spectroscopy (31P-MRS). Further, ActRIIB blockade reduces muscle capillarization, which further compounds the metabolic stress. We show that ActRIIB regulates key determinants of muscle metabolism, such as Pparβ, Pgc1α, and Pdk4 thereby optimizing different components of muscle energy metabolism. In conclusion, ActRIIB signaling endows skeletal muscle with high oxidative capacity and low fatigability. The severe metabolic side effects following ActRIIB blockade caution against deploying this strategy, at least in isolation, for treatment of neuromuscular disorders.

Item Type:Article
Refereed:Yes
Divisions:Faculty of Life Sciences > School of Biological Sciences > Biomedical Sciences
ID Code:46381
Uncontrolled Keywords:ActRIIB, myostatin, metabolic myopathy, muscle fatigue, oxidative phosphorylation, beta-oxidation, Duchenne muscular dystrophy, mdx mouse
Publisher:Nature Publishing Group

Downloads

Downloads per month over past year

University Staff: Request a correction | Centaur Editors: Update this record

Page navigation